Us Nuclear Medicine Market Size, Share Outlook, Growth Analysis Report and Forecast Trends 2026-2030

The global nuclear medicine market, spanning both diagnostic procedures (SPECT and PET imaging agents) and therapeutic radionuclides, was valued at approximately $17.8 billion in 2024 and is projected to approach $30-34 billion by 2030 at a roughly 10 percent compound annual growth rate. North America dominates the global market, underpinned by advanced imaging infrastructure, favorable regulatory pathways, and widespread clinical adoption of PET and SPECT technologies.

• •North America held the dominant global share in 2024-2025, reflecting dense network of nuclear medicine centers and high physician familiarity
• •Market encompasses two principal segments: diagnostics (larger share, driven by PET/SPECT imaging agents) and therapeutic radionuclides (fastest-growing segment)
• •Key radiopharmaceutical families include Technetium-99m-based agents, Fluorine-18 (FDG for PET), and emerging theranostic isotopes such as Lutetium-177 and Gallium-68

Rising oncological disease burden and an aging demographic profile are generating sustained demand for both diagnostic and therapeutic nuclear medicine applications across North America. Broader reimbursement coverage by public and private payers, combined with an active regulatory approval pipeline for novel radiopharmaceuticals targeting neuroendocrine tumors and prostate cancer, is expanding addressable market size.

• •Increasing incidence of cancer, cardiovascular disease, and neurological disorders drives procedural volumes and radiopharmaceutical consumption
• •Therapeutic radiophuclides (targeted radionuclide therapy) represent the highest growth sub-segment, propelled by clinical success of peptide receptor radionuclide therapy
• •New radiopharmaceutical approvals and expanded indications for existing agents are enlarging the clinical addressable market

The market bifurcates into diagnostics, encompassing SPECT agents (Technetium-99m-based) and PET agents (Fluorine-18 FDG, Ga-68, Rb-82), and therapeutics, including I-131, Y-90, Lu-177, and Ra-223 based treatments. Within North America, the United States commands the overwhelming majority of regional volume, supported by a dense network of hospital-based nuclear medicine departments and freestanding imaging centers.

• •Diagnostics represent the larger current market share, but therapeutics are expanding at a materially faster rate due to clinical momentum behind theranostics
• •PET imaging is gaining share over SPECT as newer, higher-sensitivity scanner generations diffuse through clinical practice
• •Centralized radiopharmacy distribution networks in major metro areas underpin operational efficiency across the region

Who are the notable companies in the industry?

The market structure is characterized as moderately concentrated, with a relatively small cohort of manufacturers controlling critical production infrastructure, distribution networks, and proprietary radiopharmaceutical portfolios. The industry bifurcates between fully integrated operators possessing in-house isotope production or long-term supply agreements and more specialized firms focused on formulation, regulatory filing, and commercialization of niche agents.

• •Production relies on two principal technology routes: (1) nuclear fission reactors producing Molybdenum-99 / Technetium-99m generators and (2) medical cyclotrons producing short-lived PET isotopes such as Fluorine-18 and Gallium-68
• •Manufacturing capacity for key medical isotopes is geographically concentrated in a small number of locations, creating structural supply-chain vulnerability and driving interest in domestic and regional production initiatives
• •Barriers to entry are substantial: regulatory requirements for radioisotope handling, the long lead time for cyclotron and reactor facilities, and strict Good Manufacturing Practice standards for radiopharmaceuticals

What are the recent trends and outlook?

The theranostics paradigm, combining diagnostic imaging with targeted therapeutic delivery using paired isotopes, is reshaping the clinical and commercial trajectory of the market. Domestic production initiatives and supply-chain resilience policies in North America are accelerating investment in regional cyclotron and reactor capacity, while emerging radiopharmaceuticals for oncology and neurology are expected to broaden the market significantly through 2031.

• •Emerging therapeutic agents such as Lutetium-177-labeled compounds are driving a convergence of diagnostic and therapeutic nuclear medicine under the theranostics framework
• •Supply-chain localization policies are encouraging new cyclotron and radioisotope production investments across North America to reduce dependence on foreign-sourced material
• •The North American market is projected to approach roughly $16 billion by 2031, sustaining a compound annual growth rate of approximately 14-15 percent, outpacing the global average